Martin Mackay’s rare disease startup gets $145 million as it enters the clinic
Two years ago, Martin Mackay took a couple of fellow exiles from Alexion’s 2017 culling and, after 3 decades in Big Pharma and big biotech, struck out on his own, with a vague vision that was as small as it was broad. They called it Rallybio and it was going to focus on rare diseases — they just didn’t say which of the thousands of those rare diseases that would be.
Today, they did, disclosing the first of what they say will eventually be a list of programs. And the trio — which also includes former Alexion research head Stephen Uden and Alexion tax chief Jeff Fryer — raised $145 million in Series B funding to take into the clinic, grabbing capital from the aptly named Pivotal bioVenture Partners and 10 other investment firms.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
